- 全部删除
您的购物车当前为空
Tinengotinib(替恩戈替尼)是一种多激酶抑制剂,靶向一系列参与癌细胞增殖,血管生成和免疫反应调节的激酶,包括Aurora激酶A/B、Janus激酶(JAK1/2)、成纤维细胞生长因子受体(FGFR1/2/3)、血管内皮生长因子受体(VEGFRs)等多种激酶,在多种晚期实体瘤的临床试验中显示出良好的耐受性和初步疗效。


为众多的药物研发团队赋能,
让新药发现更简单!
Tinengotinib(替恩戈替尼)是一种多激酶抑制剂,靶向一系列参与癌细胞增殖,血管生成和免疫反应调节的激酶,包括Aurora激酶A/B、Janus激酶(JAK1/2)、成纤维细胞生长因子受体(FGFR1/2/3)、血管内皮生长因子受体(VEGFRs)等多种激酶,在多种晚期实体瘤的临床试验中显示出良好的耐受性和初步疗效。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 463 | In stock | |
| 5 mg | ¥ 1,120 | In stock | |
| 10 mg | ¥ 1,650 | In stock | |
| 25 mg | ¥ 2,820 | In stock | |
| 50 mg | ¥ 3,980 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,230 | In stock |
Tinengotinib 相关产品
| 产品描述 | Tinengotinib is a multikinase inhibitor targeting a series of kinases involved in cancer cell proliferation, angiogenesis, and regulation of immune response, including Aurora kinase A/B, Janus kinase (JAK1/2), fibroblast growth factor receptor (FGFR1/2/3), vascular endothelial growth factor receptors (VEGFRs), and other tyrosine kinases. Tinengotinib has shown good tolerability and preliminary efficacy in clinical trials in a variety of advanced solid tumors. |
| 别名 | 替恩戈替尼, TT00420, TT 00420 |
| 分子量 | 394.86 |
| 分子式 | C20H19ClN6O |
| CAS No. | 2230490-29-4 |
| Smiles | ClC=1C=CC=CC1C2=NC=3C(=NNC3C)NC=4C=C(N=CC24)N5CCOCC5 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 25 mg/mL (63.31 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容